Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 (NCT00605085) | Clinical Trial Compass
CompletedPhase 3
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
2,675 participantsStarted 2005-10
Plain-language summary
The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged \> or = 18 years
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* At least 18 years of age
* Written informed consent obtained prior to study entry
Exclusion Criteria:
* Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine
* History of any previous JE vaccination (e.g. JE-VAX®)
* Immunodeficiency including post-organ-transplantation or immunosuppressive therapy
* A family history of congenital or hereditary immunodeficiency
* History of autoimmune disease
* Any acute infections within 2 weeks prior to enrollment
* Known or suspected HIV Infection
* Pregnancy, lactation or unreliable contraception in female subjects